Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | DRD4 | P21917 | 6/20 | 0.41 |
| ▸ | DRD3 | P35462 | 6/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19337433 | 0.83 | DRD2 (0.41) | DRD2DRD4DRD3WDR5L3MBTL1 | |
| SCHEMBL22639615 | 0.83 | PRSS1 (0.49) | MAPTHPGDMAOB | |
| SCHEMBL1710060 | 0.83 | NPC1 (0.47) | DRD2DRD4DRD3WDR5L3MBTL1 | |
| SCHEMBL2566681 | 0.79 | MAOB (0.49) | L3MBTL1MAPTMAOB | |
| SCHEMBL9578594 | 0.79 | LTA4H (0.44) | MAPT | |
| SCHEMBL7762488 | 0.79 | KDM4E (0.41) | DRD2DRD4DRD3L3MBTL1MAPT | |
| SCHEMBL12619607 | 0.79 | ALDH1A1 (0.44) | MAPTHPGD | |
| SCHEMBL15004512 | 0.79 | DRD2 (0.50) | DRD2DRD4DRD3L3MBTL1KCNH2 | |
| SCHEMBL24352742 | 0.79 | WDR5 (0.42) | DRD2DRD4DRD3WDR5L3MBTL1 | |
| SCHEMBL3707852 | 0.79 | TEAD4 (0.44) | DRD2DRD4DRD3WDR5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150051256-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| US-20150051256-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| US-8901171-B2 | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901171-B2 | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20130046000-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-21 | — | — | US | disclosed |
| US-20130046000-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-21 | — | — | US | disclosed |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-03-29 | — | — | US | disclosed |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-28 | — | — | US | disclosed |
| US-7960416-B2 | Oil-in-water emulsion of a 1-carboxylate-6-arylsulfamoyl cyclohexene and synthetic and naturally occurring phospholipids; nitric oxide or cytokine prodution inhibitors; cardiovascular disorders, autoimmune dieseases, septic shock; improved stability during autoclave sterilization | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20100016381-A1 | STABLE EMULSION COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090105314-A1 | Pharmaceutical Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-04-23 | — | — | US | disclosed |
| US-20090062355-A1 | Pharmaceutical Product | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-03-05 | — | — | US | disclosed |
| US-7247653-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-24 | — | — | US | disclosed |
| US-7247653-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105314-A1 | Pharmaceutical Agent | TLR1, TLR6, TPMT | DRD2 4399/4885DRD4 4668/4885DRD3 4544/4885 |
| US-20090062355-A1 | Pharmaceutical Product | ATF1, ATF4, TLR8 | DRD2 3520/4885DRD4 4602/4885DRD3 4545/4885 |
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | DRD2 2218/4885DRD4 2751/4885DRD3 3044/4885 |
| US-20130046000-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | DRD2 2218/4885DRD4 2751/4885DRD3 3044/4885 |
| US-20110184034-A1 | Severe sepsis preventive therapeutic agent | TLR1, TLR5, TLR4 | DRD2 3380/4885DRD4 4311/4885DRD3 3846/4885 |
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | DRD2 2218/4885DRD4 2751/4885DRD3 3044/4885 |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | ATF1, ATF4, TLR8 | DRD2 3520/4885DRD4 4602/4885DRD3 4545/4885 |
| US-20150051256-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | DRD2 2218/4885DRD4 2751/4885DRD3 3044/4885 |
| US-20100016381-A1 | STABLE EMULSION COMPOSITION | LIPA, PHOSPHO1, CEL | DRD2 1877/4885DRD4 2259/4885DRD3 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.